Amgen

Time to Tackle the Challenges around Combination Therapies for Cancer

29 March 2021

A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support use of…

Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology

1 February 2021

Using medicines in combination can deliver better outcomes for patients across different tumour types and disease stages. Yet many HTA agencies do not find that the…

Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?

1 February 2021

This research paper examines whether value of a life estimates used in economic evaluation differs between government departments in a selection of developed countries. The authors find that generally estimates used in transport and the environment exceeded those used in health, which suggests that health may be undervalued by departments of health compared to departments of transport or environment.